Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.
| Revenue (Most Recent Fiscal Year) | $9.68M |
| Net Income (Most Recent Fiscal Year) | $-250.64M |
| PE Ratio (Current Year Earnings Estimate) | 199.00 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 145.46 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 67.34 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2588.18% |
| Net Margin (Trailing 12 Months) | -2588.21% |
| Return on Equity (Trailing 12 Months) | 2317.96% |
| Return on Assets (Trailing 12 Months) | 49.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.09 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.83 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 4.46 |
| Inventory Turnover (Trailing 12 Months) | 1.53 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.01 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.91 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.34 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 353.93M |
| Free Float | 187.23M |
| Market Capitalization | $1.41B |
| Average Volume (Last 20 Days) | 5.68M |
| Beta (Past 60 Months) | 1.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 47.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 33.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |